title: Apolipoprotein profiles in subjects with and without peripheral artery disease.
abstract: We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53% in the PAD group untreated with statins, 29% in the treated PAD group, and 13% in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.
authors.affiliation: Reynolds Oklahoma Center on Aging, Donald W Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. andrew-gardner@ouhsc.edu
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Gardner
authors.forename: Petar
authors.initials: P
authors.lastname: Alaupovic
authors.forename: Donald E
authors.initials: DE
authors.lastname: Parker
authors.forename: Polly S
authors.initials: PS
authors.lastname: Montgomery
authors.forename: Ashley
authors.initials: A
authors.lastname: Roof
authors.forename: Ana I
authors.initials: AI
authors.lastname: Casanegra
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D055109:Ankle Brachial Index / Q000379:methods; D001053:Apolipoproteins / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood* / Q000188:drug therapy; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides
keywords: apolipoproteins; intermittent claudication; lipids; peripheral artery disease; statins